- Subungual Melanoma Diagnostic Support Software -


What is the disease?
What does it do?

Subungual melanoma, a form of skin cancer originating in the nail unit,
is a rare and difficult condition to diagnose. Our software, developed in
Japan and the first of its kind in the world, is designed to aid doctors in
identifying this illness.

Due to the rarity of the disease, few doctors are equipped to diagnose
it, and traditional diagnostic methods require removing the affected nail,
which may not regrow afterwards. Additionally, the disease is not widely
recognized globally. Late detection can lead to severe mental and physical
burden for patients, which can ultimately lead to amputation of a digit.

What kind of examination
does it provide?

Our diagnostic system allows for non-invasive testing. Doctors photograph the affected area with a digital camera, placing no burden on the patient. The software installed on the computer then analyzes these images, assisting doctors in diagnosing the disease. In the workflow from capturing images to diagnosis, our system plays a crucial role in image extraction and analysis.

Software features
(medical explanation)

This software provides support for doctors in diagnosing dermoscopic images of nail pigmentation streaks. Despite the current trend of employing AI technologies for image analysis, recent studies from the European Dermatology AI Diagnosis Research Group, utilizing over 50,000 cases, suggest AI's recognition ability is relatively low for diagnosing subungual melanoma.
Instead of relying on AI, our software quantifies the diversity of nail color tones based on RGB values in dermoscopic images, and identifies subungual melanoma through an objective differential index (Di). As a result, our software's Area Under the Curve (AUC) when using the final diagnosis noted in the medical record as the gold standard exceeded previously reported values using AI algorithms. Furthermore, our research shows that the software's ability to distinguish between benign and malignant conditions surpasses that of qualified dermatologists.
Current definitive diagnosis for suspected nail pigmentation streaks involves total nail avulsion biopsy under local anesthesia. This invasive test often results in the semi-permanent loss of the nail. Given the rarity of subungual melanoma, dermatologists find it challenging to gain experience in assessing this disease. Our software offers an objective Di value, addressing these issues by compensating for differences in medical experience among doctors among physicians, standardizing the level of care, reducing the occurrence of overlooked early-stage melanomas, and avoiding excessive pathological tests.

Sales/Service base

Q'sfix Corporation

Headquarters: Marunouchi 1-chome 7-12 Sapia Tower 26F,
Chiyoda-ku, Tokyo, 100-0005
TEL: +81-3-6256-0330

Production base

Human Engineering Corporation

Shizuoka Headquarters: 166-3 Araya, Mishima-shi,
Shizuoka, 411-0834